MedTrace Logo

Abuse Liability for Eight Electronic Nicotine Products

NCT07323511 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-01-07

No results posted yet for this study

Summary

This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \[PD\]), and plasma nicotine uptake (pharmacokinetics \[PK\]) during and following ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.

Conditions

  • Smoking
  • Smoking Behaviors
  • Tobacco Use
  • Tobacco Smoking

Interventions

OTHER

Product A

Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette

OTHER

Product B

Tobacco Flavor, 5%

OTHER

Product C

Tobacco Flavor, 1.5%

OTHER

Product D

Tobacco Flavor, 5%

OTHER

Product E

Tobacco Flavor, 2.4%

OTHER

Product F

Tobacco Flavor, 5%

OTHER

Product G

Mint Flavor, 5%

OTHER

Product N

Nicorette® White Ice Mint 4 mg nicotine polacrilex gum

Sponsors & Collaborators

  • RAI Services Company

    lead INDUSTRY

Principal Investigators

  • Milly Kanobe · Reynolds American

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2026-04-15
Completion
2026-09-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07323511 on ClinicalTrials.gov